Lisa J. Alcock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lisa J. Alcock has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Yu Heng Lau
The University of Sydney
8 shared publications Haritha Krishna Sudhakar
School of Chemistry
5 shared publicationsJoshua Mills
School of Chemistry A
3 shared publications- Justin M. Chalker
Flinders University
3 shared publications - Michael Victor Perkins
Flinders University
3 shared publications - Toby Passioura
The University of Sydney
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 79 (10)
Phage display identifies macrocyclic peptides that bind the TRF2TRFH domain
Telomeric Repeat Binding Factor 2 (TRF2) is a subunit of the Shelterin protein complex that binds to telomeric DNA. TRF2 is a potential drug target for cancer therapy, as the genomic instability of cancer cells can result in telomeric fragility that is suppressed by overexpression of Shelterin proteins. In this study, we used phage display to screen for disulfide-cyclised peptides that bind the TRFH domain of TRF2, which is responsible for both homodimerisation and mediating the recruitment of accessory proteins. Enriched peptide sequences were resynthesised on standard solid-phase peptide synthesis and were shown to bind TRFH with micromolar affinity in biophysical assays. A macrocyclic analogue featuring a methylene crosslink between cysteine sidechains retained binding to TRFH. Sequence alignment and molecular modelling predicted that the bound poses of the enriched peptide sequences recapitulate the core binding motif found in TRFH-binding accessory proteins. This work demonstrates that phage display is a viable strategy for discovering novel peptide binders for TRF2, paving the way for screening and optimising modified peptides with greater functionality in future phage display campaigns.
- 23 October 2026
- Published by CSIRO Publishing in Australian Journal of Chemistry
- Vol. 79 (10)
Open AccessPhage display identifies macrocyclic peptides that bind the TRF2TRFH domain
Telomeric Repeat Binding Factor 2 (TRF2) is a subunit of the Shelterin protein complex that binds to telomeric DNA. TRF2 is a potential drug target for cancer therapy, as the genomic instability of cancer cells can result in telomeric fragility that is suppressed by overexpression of Shelterin proteins. In this study, we used phage display to screen for disulfide-cyclised peptides that bind the TRFH domain of TRF2, which is responsible for both homodimerisation and mediating the recruitment of accessory proteins. Enriched peptide sequences were resynthesised on standard solid-phase peptide synthesis and were shown to bind TRFH with micromolar affinity in biophysical assays. A macrocyclic analogue featuring a methylene crosslink between cysteine sidechains retained binding to TRFH. Sequence alignment and molecular modelling predicted that the bound poses of the enriched peptide sequences recapitulate the core binding motif found in TRFH-binding accessory proteins. This work demonstrates that phage display is a viable strategy for discovering novel peptide binders for TRF2, paving the way for screening and optimising modified peptides with greater functionality in future phage display campaigns.
- 14 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 24672-24683
Cell-Active Peptide Inhibitors of the FANCM-RMI Interaction
The FANCM-RMI protein-protein interaction plays an essential role in cancers that extend their telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. Here, we report the first cell-active peptide inhibitors of FANCM-RMI. Screening of mRNA-displayed peptide libraries treated with trans-1,4-dibromo-2-butene led to the discovery of both linear and cyclic peptide hits that bind RMI at the FANCM interaction site. The most potent peptides engage RMI with nanomolar affinity (KD = 4-31 nM) and outcompete the native peptide mimic of FANCM (IC50 = 24-155 nM). A bound X-ray crystal structure of the top hit revealed novel interactions at the RMI binding site that were not found in the native interaction. Conjugation to a cell-penetrating peptide resulted in inhibitors that induced an antiproliferative effect in ALT-positive osteosarcoma cell lines. These inhibitors represent the first bioactive RMI binders that can be used as chemical tools for studying the involvement of FANCM-RMI in ALT-driven cancers.
- 14 November 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (22) , 24672-24683
Cell-Active Peptide Inhibitors of the FANCM-RMI Interaction
The FANCM-RMI protein-protein interaction plays an essential role in cancers that extend their telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. Here, we report the first cell-active peptide inhibitors of FANCM-RMI. Screening of mRNA-displayed peptide libraries treated with trans-1,4-dibromo-2-butene led to the discovery of both linear and cyclic peptide hits that bind RMI at the FANCM interaction site. The most potent peptides engage RMI with nanomolar affinity (KD = 4-31 nM) and outcompete the native peptide mimic of FANCM (IC50 = 24-155 nM). A bound X-ray crystal structure of the top hit revealed novel interactions at the RMI binding site that were not found in the native interaction. Conjugation to a cell-penetrating peptide resulted in inhibitors that induced an antiproliferative effect in ALT-positive osteosarcoma cell lines. These inhibitors represent the first bioactive RMI binders that can be used as chemical tools for studying the involvement of FANCM-RMI in ALT-driven cancers.
- Open Access
- 5 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Cell-active peptide inhibitors of the FANCM-RMI interaction
The FANCM-RMI protein-protein interaction plays an essential role in cancers that extend their telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. Here, we report the first cell-active peptide inhibitors of FANCM-RMI. Screening of mRNA-displayed peptide libraries treated with trans-1,4-dibromo-2-butene led to the discovery of both linear and cyclic peptide hits that bind RMI at the FANCM interaction site. The most potent peptides engage RMI with nanomolar affinity (KD = 4-31 nM) and outcompete the native peptide mimic of FANCM (IC50 = 24-155 nM). A bound X-ray crystal structure of the top hit revealed novel interactions at the RMI binding site not found in the native interaction. Conjugation to a cell-penetrating peptide resulted in inhibitors that induced an antiproliferative effect in ALT-positive osteosarcoma cell lines. These inhibitors represent the first bioactive RMI binders that can be used as chemical tools for studying the involvement of FANCM-RMI in ALT-driven cancers.
- 5 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessCell-active peptide inhibitors of the FANCM-RMI interaction
The FANCM-RMI protein-protein interaction plays an essential role in cancers that extend their telomeres through the Alternative Lengthening of Telomeres (ALT) pathway. Here, we report the first cell-active peptide inhibitors of FANCM-RMI. Screening of mRNA-displayed peptide libraries treated with trans-1,4-dibromo-2-butene led to the discovery of both linear and cyclic peptide hits that bind RMI at the FANCM interaction site. The most potent peptides engage RMI with nanomolar affinity (KD = 4-31 nM) and outcompete the native peptide mimic of FANCM (IC50 = 24-155 nM). A bound X-ray crystal structure of the top hit revealed novel interactions at the RMI binding site not found in the native interaction. Conjugation to a cell-penetrating peptide resulted in inhibitors that induced an antiproliferative effect in ALT-positive osteosarcoma cell lines. These inhibitors represent the first bioactive RMI binders that can be used as chemical tools for studying the involvement of FANCM-RMI in ALT-driven cancers.
- 6 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (12) , 12615-12625
Potent Cyclic Peptide Inhibitors Disrupt the FANCM–RMI Interaction
FANCM-RMI is a protein-protein interaction that maintains genome stability during DNA repair events in cancers that rely on the Alternative Lengthening of Telomeres (ALT) pathway for survival. We report the first valid chemical inhibitors of the FANCM-RMI interaction discovered by screening cyclic peptides via mRNA display. These inhibitors engage the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2-10 nM) and are potent disruptors of the FANCM-RMI interaction (IC50 = 54-104 nM). X-ray crystallography and alanine scanning reveal novel binding modes and interactions between the cyclic peptides and RMI1/2 that drive high-potency inhibition. Co-immunoprecipitation studies confirm the complete disruption of the native interaction in whole osteosarcoma cell lysates. These inhibitors represent the first validated RMI binders toward developing chemical tools for interrogating the mechanistic roles of FANCM-RMI in mediating genome stability and provide a much-anticipated starting point to accelerate the development of FANCM-RMI inhibitors for intervention against ALT-driven cancers.
- 6 June 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (12) , 12615-12625
Potent Cyclic Peptide Inhibitors Disrupt the FANCM–RMI Interaction
FANCM-RMI is a protein-protein interaction that maintains genome stability during DNA repair events in cancers that rely on the Alternative Lengthening of Telomeres (ALT) pathway for survival. We report the first valid chemical inhibitors of the FANCM-RMI interaction discovered by screening cyclic peptides via mRNA display. These inhibitors engage the FANCM-binding pocket of RMI1/2 with nanomolar affinity (KD = 2-10 nM) and are potent disruptors of the FANCM-RMI interaction (IC50 = 54-104 nM). X-ray crystallography and alanine scanning reveal novel binding modes and interactions between the cyclic peptides and RMI1/2 that drive high-potency inhibition. Co-immunoprecipitation studies confirm the complete disruption of the native interaction in whole osteosarcoma cell lysates. These inhibitors represent the first validated RMI binders toward developing chemical tools for interrogating the mechanistic roles of FANCM-RMI in mediating genome stability and provide a much-anticipated starting point to accelerate the development of FANCM-RMI inhibitors for intervention against ALT-driven cancers.
- 1 July 2024
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 22 (30) , 6095-6102
Accessing diverse bicyclic peptide conformations using 1,2,3-TBMB as a linker
Bicyclic peptides are a powerful modality for engaging challenging drug targets such as protein–protein interactions. Here, we use 1,2,3-tris(bromomethyl)benzene (1,2,3-TBMB) to access bicyclic peptides with diverse conformations that differ from conventional bicyclisation products formed with 1,3,5-TBMB. Bicyclisation at cysteine residues under aqueous buffer conditions proceeds efficiently, with broad substrate scope, compatibility with high-throughput screening, and clean conversion (>90%) for 96 of the 115 peptides tested. We envisage that the 1,2,3-TBMB linker will be applicable to a variety of peptide screening techniques in drug discovery.
- 1 July 2024
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 22 (30) , 6095-6102
Accessing diverse bicyclic peptide conformations using 1,2,3-TBMB as a linker
Bicyclic peptides are a powerful modality for engaging challenging drug targets such as protein–protein interactions. Here, we use 1,2,3-tris(bromomethyl)benzene (1,2,3-TBMB) to access bicyclic peptides with diverse conformations that differ from conventional bicyclisation products formed with 1,3,5-TBMB. Bicyclisation at cysteine residues under aqueous buffer conditions proceeds efficiently, with broad substrate scope, compatibility with high-throughput screening, and clean conversion (>90%) for 96 of the 115 peptides tested. We envisage that the 1,2,3-TBMB linker will be applicable to a variety of peptide screening techniques in drug discovery.
- 25 April 2024
- Published by Elsevier
- Vol. 698, 361-378
Fluorescence polarization assay for screening FANCM-RMI inhibitors to target the alternative lengthening of telomeres
- 25 April 2024
- Published by Elsevier
- Vol. 698, 361-378
Fluorescence polarization assay for screening FANCM-RMI inhibitors to target the alternative lengthening of telomeres
- Open Access
- 5 February 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Accessing diverse bicyclic peptide conformations using 1,2,3-TBMB as a linker
Bicyclic peptides are a powerful modality for the engagement of challenging drug targets such as protein-protein interactions. The most common crosslinkers used to generate bicyclic peptides are C3-symmetrical, with evenly positioned peptide loops facing radially outwards from a linker core to favour globular conformations. In contrast, linkers with alternative symmetries can potentially provide access to a more diverse conformational landscape of bicyclic peptides. Here, we use 1,2,3-tris(bromomethyl) benzene (1,2,3-TBMB) to access bicyclic peptides with multiple isomeric configurations, leading to conformations that differ substantially from both the parent linear peptides and the conventional bicyclization products formed with 1,3,5-TBMB, as observed in 2D NMR and CD experiments. Bicyclization at cysteine residues proceeds efficiently under standard aqueous buffer conditions, with broad substrate scope, compatibility with high-throughput screening, and clean conversion (>90%) of linear precursors to bicyclic products for 88 of the 106 diverse peptide sequences tested. We envisage that the 1,2,3-TBMB linker will be applicable to a variety of peptide screening techniques, thereby enabling the discovery of unconventional bicyclic peptides that can engage a broad range of novel drug targets.
- 5 February 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessAccessing diverse bicyclic peptide conformations using 1,2,3-TBMB as a linker
Bicyclic peptides are a powerful modality for the engagement of challenging drug targets such as protein-protein interactions. The most common crosslinkers used to generate bicyclic peptides are C3-symmetrical, with evenly positioned peptide loops facing radially outwards from a linker core to favour globular conformations. In contrast, linkers with alternative symmetries can potentially provide access to a more diverse conformational landscape of bicyclic peptides. Here, we use 1,2,3-tris(bromomethyl) benzene (1,2,3-TBMB) to access bicyclic peptides with multiple isomeric configurations, leading to conformations that differ substantially from both the parent linear peptides and the conventional bicyclization products formed with 1,3,5-TBMB, as observed in 2D NMR and CD experiments. Bicyclization at cysteine residues proceeds efficiently under standard aqueous buffer conditions, with broad substrate scope, compatibility with high-throughput screening, and clean conversion (>90%) of linear precursors to bicyclic products for 88 of the 106 diverse peptide sequences tested. We envisage that the 1,2,3-TBMB linker will be applicable to a variety of peptide screening techniques, thereby enabling the discovery of unconventional bicyclic peptides that can engage a broad range of novel drug targets.
- Open Access
- 17 April 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Mannich base PIP-199 is a chemically unstable pan-assay interference compound
PIP-199 is the only reported small molecule inhibitor of FANCM-RMI, a key protein-protein interaction that governs genome instability in the genetic disorders Fanconi Anemia and Bloom’s Syndrome. PIP-199 and close analogues that share the same indole-derived Mannich base core scaffold have been used as commercially available tool compounds for studying a wide range of therapeutically relevant biological pathways and targets, including the Alternative Lengthening of Telomeres (ALT), G-quadruplexes, pro-apoptotic proteins, and quorum sensing. Herein, we report the first published synthesis of PIP-199 and related analogues, demonstrating that the parent compound immediately decomposes in common aqueous buffers and some organic solvents. We characterize the breakdown products and show that PIP-199 and its more hydrolytically stable analogues show no observable activity in binding and competitive biophysical assays for FANCM-RMI. We conclude that PIP-199 is not an effective tool compound for biological studies, and that apparent activity in cellular studies likely arises from non-specific toxicity of mixed breakdown products. More generally, apparent inhibitors that share this indole-derived Mannich scaffold potentially represent a new family of pan-assay interference compounds (PAINS) that should be thoroughly assessed for aqueous stability prior to use in biological studies.
- 17 April 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMannich base PIP-199 is a chemically unstable pan-assay interference compound
PIP-199 is the only reported small molecule inhibitor of FANCM-RMI, a key protein-protein interaction that governs genome instability in the genetic disorders Fanconi Anemia and Bloom’s Syndrome. PIP-199 and close analogues that share the same indole-derived Mannich base core scaffold have been used as commercially available tool compounds for studying a wide range of therapeutically relevant biological pathways and targets, including the Alternative Lengthening of Telomeres (ALT), G-quadruplexes, pro-apoptotic proteins, and quorum sensing. Herein, we report the first published synthesis of PIP-199 and related analogues, demonstrating that the parent compound immediately decomposes in common aqueous buffers and some organic solvents. We characterize the breakdown products and show that PIP-199 and its more hydrolytically stable analogues show no observable activity in binding and competitive biophysical assays for FANCM-RMI. We conclude that PIP-199 is not an effective tool compound for biological studies, and that apparent activity in cellular studies likely arises from non-specific toxicity of mixed breakdown products. More generally, apparent inhibitors that share this indole-derived Mannich scaffold potentially represent a new family of pan-assay interference compounds (PAINS) that should be thoroughly assessed for aqueous stability prior to use in biological studies.
- Open Access
- 9 December 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (23) , 2313-2326
Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) accounts for more than half of Philadelphia chromosome-like (Ph-like) ALL and is associated with a poor outcome in children and adults. Overexpression of CRLF2 results in activation of Janus kinase (JAK)-STAT and parallel signaling pathways in experimental models, but existing small molecule inhibitors of JAKs show variable and limited efficacy. Here, we evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against JAKs. Solving the structure of type I JAK inhibitors ruxolitinib and baricitinib bound to the JAK2 tyrosine kinase domain enabled the rational design and optimization of a series of cereblon (CRBN)-directed JAK PROTACs utilizing derivatives of JAK inhibitors, linkers, and CRBN-specific molecular glues. The resulting JAK PROTACs were evaluated for target degradation, and activity was tested in a panel of leukemia/lymphoma cell lines and xenograft models of kinase-driven ALL. Multiple PROTACs were developed that degraded JAKs and potently killed CRLF2r cell lines, the most active of which also degraded the known CRBN neosubstrate GSPT1 and suppressed proliferation of CRLF2r ALL in vivo, e.g. compound 7 (SJ988497). Although dual JAK/GSPT1-degrading PROTACs were the most potent, the development and evaluation of multiple PROTACs in an extended panel of xenografts identified a potent JAK2-degrading, GSPT1-sparing PROTAC that demonstrated efficacy in the majority of kinase-driven xenografts that were otherwise unresponsive to type I JAK inhibitors, e.g. compound 8 (SJ1008030). Together, these data show the potential of JAK-directed protein degradation as a therapeutic approach in JAK-STAT–driven ALL and highlight the interplay of JAK and GSPT1 degradation activity in this context.
- 9 December 2021
- Published by American Society of Hematology in Blood
- Vol. 138 (23) , 2313-2326
Open AccessDegradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia
CRLF2-rearranged (CRLF2r) acute lymphoblastic leukemia (ALL) accounts for more than half of Philadelphia chromosome-like (Ph-like) ALL and is associated with a poor outcome in children and adults. Overexpression of CRLF2 results in activation of Janus kinase (JAK)-STAT and parallel signaling pathways in experimental models, but existing small molecule inhibitors of JAKs show variable and limited efficacy. Here, we evaluated the efficacy of proteolysis-targeting chimeras (PROTACs) directed against JAKs. Solving the structure of type I JAK inhibitors ruxolitinib and baricitinib bound to the JAK2 tyrosine kinase domain enabled the rational design and optimization of a series of cereblon (CRBN)-directed JAK PROTACs utilizing derivatives of JAK inhibitors, linkers, and CRBN-specific molecular glues. The resulting JAK PROTACs were evaluated for target degradation, and activity was tested in a panel of leukemia/lymphoma cell lines and xenograft models of kinase-driven ALL. Multiple PROTACs were developed that degraded JAKs and potently killed CRLF2r cell lines, the most active of which also degraded the known CRBN neosubstrate GSPT1 and suppressed proliferation of CRLF2r ALL in vivo, e.g. compound 7 (SJ988497). Although dual JAK/GSPT1-degrading PROTACs were the most potent, the development and evaluation of multiple PROTACs in an extended panel of xenografts identified a potent JAK2-degrading, GSPT1-sparing PROTAC that demonstrated efficacy in the majority of kinase-driven xenografts that were otherwise unresponsive to type I JAK inhibitors, e.g. compound 8 (SJ1008030). Together, these data show the potential of JAK-directed protein degradation as a therapeutic approach in JAK-STAT–driven ALL and highlight the interplay of JAK and GSPT1 degradation activity in this context.
- 4 December 2019
- Published by Wiley in ChemBioChem
- Vol. 21 (9) , 1329-1334
Proteome‐Wide Survey of Cysteine Oxidation by Using a Norbornene Probe
Rapid detection of cysteine oxidation in living cells is critical in advancing our understanding of responses to reactive oxygen species (ROS) and oxidative stress. Accordingly, there is a need to develop chemical probes that facilitate proteome‐wide detection of cysteine's many oxidation states. Herein, we report the first whole‐cell proteomics analysis using a norbornene probe to detect the initial product of cysteine oxidation: cysteine sulfenic acid. The oxidised proteins identified in the HeLa cell model represent the first targets of the ROS hydrogen peroxide. The panel of protein hits provides new and important information about the targets of oxidative stress, including 148 new protein members of the sulfenome. These findings provide new leads for the study and understanding of redox signalling and diseases associated with oxidative stress.
- 4 December 2019
- Published by Wiley in ChemBioChem
- Vol. 21 (9) , 1329-1334
Proteome‐Wide Survey of Cysteine Oxidation by Using a Norbornene Probe
Rapid detection of cysteine oxidation in living cells is critical in advancing our understanding of responses to reactive oxygen species (ROS) and oxidative stress. Accordingly, there is a need to develop chemical probes that facilitate proteome‐wide detection of cysteine's many oxidation states. Herein, we report the first whole‐cell proteomics analysis using a norbornene probe to detect the initial product of cysteine oxidation: cysteine sulfenic acid. The oxidised proteins identified in the HeLa cell model represent the first targets of the ROS hydrogen peroxide. The panel of protein hits provides new and important information about the targets of oxidative stress, including 148 new protein members of the sulfenome. These findings provide new leads for the study and understanding of redox signalling and diseases associated with oxidative stress.